Juhasz, Attila
Wu, Jingtao
Hisada, Michie
Tsukada, Tomoka
Jeong, Myung Ho
Funding for this research was provided by:
Takeda Development Center Asia, Pte. Ltd.
Takeda Pharmaceuticals International AG. Ltd.
Article History
Received: 4 September 2017
Accepted: 15 January 2018
First Online: 7 February 2018
Ethics approval and consent to participate
: The Institutional Review Boards at each of the 30 study sites were responsible for approval of the clinical study conduct in accordance with ethical principles and the Guidelines of the Declaration of Helsinki, the regulations and guidelines of the International Conference on Harmonisation, Harmonised Tripartite Guideline for Good Clinical Practice, and all applicable local regulations (Additional file InternalRef removed: Table S2). All patients provided written informed consent prior to screening.
: Not applicable.
: AJ was an employee of Takeda Development Centre Europe, Ltd. during the time when the study was conducted. JW and MH are employees of Takeda Development Center Americas, Inc. TT is an employee of Takeda Pharmaceutical Company Ltd., and was an employee of Takeda Development Center Asia, Pte. Ltd. during the time when the study was conducted. MHJ is a TAK-491-307 investigator and Professor of Chonnam National University Hospital, Director of Heart Research Center Nominated by Korea, Ministry of Health and Welfare, Principal Investigator of Korea Acute Myocardial Infarction Registry, and Director of Korea Cardiovascular Stent Research Institute.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.